Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags BB-1701

Tag: BB-1701

Unlocking the Potential of Antibody-drug Conjugates

Toshimitsu Uenaka, Ph.D.
One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He...

Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...

ADC Review | Editorial Team
Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X